Letters patients with nonsquamous non–small cell lung cancer in our Bristol-Myers Squibb Co Ltd, Eli Lilly Japan K. K., Ono Pharmaceutical Co Ltd, and cohort at the 6-week landmark analysis of progression-free sur- Taiho Pharmaceutical Co Ltd; lecture fees from Chugai Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MSD K. K., and Pfizer Japan Inc; and research funding vival (PFS), with 43 of these patients having a PD-L1 TPS of less from Ono Pharmaceutical Co Ltd. Dr Nakagawa has received honoraria from than 50% and 11 a PD-L1 TPS of 50% or greater. These num- Astellas Pharma Inc, AstraZeneca K. K., Ayumi Pharmaceutical Corp, Boehringer bers are too small to allow detection of a statistically signifi- Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Chugai Pharmaceutical Co Ltd, cant difference in PFS in either subgroup between individu- Daiichi Sankyo Co Ltd, Eli Lilly Japan K. K., Kissei Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MSD K. K., Novartis Pharma K. K., Ono Pharmaceutical Co Ltd, als with irAEs and those without irAEs. However, there was a Pfizer Japan Inc, Showa Yakuhin Kako Co Ltd, Sym Bio Pharmaceuticals Ltd, and nonsignificant finding of a longer PFS in patients with irAEs Taiho Pharmaceutical Co Ltd; research funding from AbbVie Inc, Astellas Pharma than in those without such events for the subgroups with either Inc, AstraZeneca K. K., Boehringer Ingelheim Japan Inc, Bristol-Myers Squibb Co Ltd, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Eli Lilly Japan K. K., GlaxoSmithKline K. K., a low (hazard ratio, 0.58; 95% CI, 0.29-1.16; log-rank P = .12) Kyowa Hakko Kirin Co Ltd, Merck Serono Co Ltd, MSD K. K., Novartis Pharma K. K., or high (hazard ratio, 0.19; 95% CI, 0.008-2.05; log-rank P = .16) Ono Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Pfizer Japan Inc, Taiho PD-L1 TPS. Although further studies will be needed to con- Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, and Yakult Honsha Co Ltd; firm these preliminary findings, they suggest that the occur- and consulting or advisory fees from Astellas Pharma Inc, Eli Lilly Japan K. K., and Ono Pharmaceutical Co Ltd. No other disclosures are reported. rence of irAEs may be predictive of nivolumab efficacy at least 1. Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse in part in a manner independent of the PD-L1 expression level events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol. 2018; on tumor cells. 4(3):374-378. 2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in Koji Haratani, MD advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17): Hidetoshi Hayashi, MD, PhD 1627-1639. Kazuhiko Nakagawa, MD, PhD Author Affiliations: Department of Medical Oncology, Kindai University Faculty CORRECTION of Medicine, Osaka-Sayama, Osaka, Japan. Incorrect Email Address for Corresponding Author: In the Research Letter titled Corresponding Author: Hidetoshi Hayashi, MD, PhD, Department of Medical “Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, With Negative Results,” published online May 3, 2018, and in this issue of JAMA Osaka-Sayama, Osaka 589-8511, Japan ([email protected]). Oncology,1 Dr McCarthy’s email address was incorrect. In the Corresponding Au- Published Online: May 31, 2018. doi:10.1001/jamaoncol.2018.0751 thor portion of the Article Information section, her email address should have been Conflict of Interest Disclosures: Dr Haratani has received honoraria from Ono listed as “[email protected].” This article was corrected online. Pharmaceutical Co Ltd, as well as lecture fees from Pfizer Japan Inc, 1. McCarthy AM, Barlow WE, Conant EF, et al. Breast cancer with a poor AstraZeneca K. K., and Bristol-Myers Squibb Co Ltd. Dr Hayashi has received prognosis diagnosed after screening mammography with negative results honoraria from AstraZeneca K. K., Boehringer Ingelheim Japan Inc, [published online May 3, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.0352 1018 JAMA Oncology July 2018 Volume 4, Number 7 (Reprinted) jamaoncology.com © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021.